{"id":"geodon-ziprasidone","safety":{"commonSideEffects":[{"rate":"31%","effect":"Somnolence"},{"rate":"10-14%","effect":"Akathisia"},{"rate":"8-10%","effect":"Extrapyramidal symptoms"},{"rate":"9-16%","effect":"Dizziness"},{"rate":"8-10%","effect":"Nausea"},{"rate":null,"effect":"QT prolongation"},{"rate":"1-3%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1375743","moleculeType":"Small molecule","molecularWeight":"467.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ziprasidone antagonizes dopamine D2 receptors, which reduces psychotic symptoms, and also blocks serotonin 5-HT2A receptors, which may improve mood and reduce extrapyramidal side effects. It has a rapid onset of action and is notable for minimal weight gain compared to other atypical antipsychotics.","oneSentence":"Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:21.548Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Acute agitation in patients with schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"}]},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT00288353","phase":"PHASE3","title":"Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2006-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":48},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT03781115","phase":"PHASE1","title":"Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2017-11-20","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT01172652","phase":"PHASE4","title":"Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)","status":"COMPLETED","sponsor":"VA Palo Alto Health Care System","startDate":"2010-04","conditions":"Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder","enrollment":49},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT00254202","phase":"PHASE3","title":"Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2005-11-18","conditions":"Schizophrenia","enrollment":593},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT02504450","phase":"","title":"Outcomes of Antipsychotic Medication Used in the Emergency Department","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-04","conditions":"Agitation,Psychomotor","enrollment":93},{"nctId":"NCT01006551","phase":"PHASE2","title":"Ziprasidone in Early Onset Schizophrenia Spectrum Disorders","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2002-12","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT00635700","phase":"PHASE2","title":"Ziprasidone in the Psychosis Prodrome","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-03","conditions":"Psychosis Prodrome","enrollment":51},{"nctId":"NCT00538629","phase":"","title":"Non Interventional Study In Bipolar Disorder And Schizophrenia With Zeldox","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-16","conditions":"Bipolar Disorder, Schizophrenia","enrollment":471},{"nctId":"NCT00448630","phase":"","title":"An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-23","conditions":"Schizophrenia, Metabolic Syndrome X","enrollment":328},{"nctId":"NCT03837860","phase":"EARLY_PHASE1","title":"Reducing the Abuse of Opioids in Drug Users","status":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-04-01","conditions":"Opioid Abuse, Unspecified, Opioid Dependence","enrollment":3},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT02075047","phase":"PHASE3","title":"Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2014-05-23","conditions":"Bipolar Disorder","enrollment":171},{"nctId":"NCT03768726","phase":"PHASE3","title":"Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2018-12-21","conditions":"Bipolar Disorder","enrollment":23},{"nctId":"NCT00406315","phase":"PHASE4","title":"Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":255},{"nctId":"NCT00312494","phase":"PHASE3","title":"3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-04","conditions":"Bipolar Disorder","enrollment":680},{"nctId":"NCT00329108","phase":"PHASE4","title":"Ziprasidone And Olanzapine's Outcomes In Mania","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11","conditions":"Acute Mania, Bipolar Disorder, Manic","enrollment":29},{"nctId":"NCT00282464","phase":"PHASE3","title":"A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-02","conditions":"Bipolar Disorder","enrollment":392},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00265330","phase":"PHASE3","title":"Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-03","conditions":"Bipolar Disorder","enrollment":169},{"nctId":"NCT00257192","phase":"PHASE3","title":"Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-04","conditions":"Schizophrenia","enrollment":284},{"nctId":"NCT00141271","phase":"PHASE3","title":"A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Bipolar Disorder","enrollment":536},{"nctId":"NCT00280566","phase":"PHASE3","title":"Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-12","conditions":"Bipolar Mania, Bipolar Disorder","enrollment":584},{"nctId":"NCT00174447","phase":"PHASE3","title":"Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-10","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT00483548","phase":"PHASE3","title":"Adjunctive Ziprasidone in the Treatment of Bipolar I Depression","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10","conditions":"Bipolar Disorder, Depression, Bipolar","enrollment":298},{"nctId":"NCT00579670","phase":"","title":"Treatment of Schizophrenic Patients With Ziprasidone","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT00257166","phase":"PHASE3","title":"Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-01","conditions":"Bipolar Disorder","enrollment":238},{"nctId":"NCT00748566","phase":"PHASE4","title":"One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-12","conditions":"Schizophrenia and Disorders With Psychotic Features","enrollment":172},{"nctId":"NCT00265382","phase":"PHASE3","title":"Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-06","conditions":"Schizophrenia","enrollment":221},{"nctId":"NCT00139737","phase":"PHASE3","title":"Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-03","conditions":"Schizophrenia","enrollment":344},{"nctId":"NCT00723606","phase":"PHASE3","title":"A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":376},{"nctId":"NCT01113541","phase":"PHASE3","title":"One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-07","conditions":"Bipolar Disorder","enrollment":13},{"nctId":"NCT01053429","phase":"","title":"A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-06","conditions":"Bipolar Disorder, Schizophrenia","enrollment":3391},{"nctId":"NCT00137020","phase":"PHASE4","title":"Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":"Schizophrenia, Psychotic Disorders","enrollment":294},{"nctId":"NCT00650429","phase":"PHASE4","title":"A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-10","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":28},{"nctId":"NCT00821444","phase":"PHASE1","title":"Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2009-01","conditions":"Healthy","enrollment":11},{"nctId":"NCT00645229","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1},{"nctId":"NCT00645515","phase":"PHASE3","title":"A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-06","conditions":"Schizophrenia","enrollment":240},{"nctId":"NCT00143351","phase":"PHASE3","title":"Mozart Relapse Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-06","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00159770","phase":"PHASE3","title":"Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-11","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorders","enrollment":290},{"nctId":"NCT00136994","phase":"PHASE3","title":"IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-03","conditions":"Schizophrenia","enrollment":160},{"nctId":"NCT00649064","phase":"PHASE4","title":"A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-12","conditions":"Schizoaffective Disorder, Schizophrenia","enrollment":46},{"nctId":"NCT01124877","phase":"PHASE3","title":"Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-07","conditions":"Bipolar Disorder","enrollment":""},{"nctId":"NCT01117220","phase":"PHASE3","title":"Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-06","conditions":"Bipolar Disorder","enrollment":""},{"nctId":"NCT00645320","phase":"PHASE4","title":"A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-08","conditions":"Pyschotic Disorders","enrollment":75},{"nctId":"NCT00650611","phase":"PHASE2","title":"A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-12","conditions":"Schizophrenia, Bipolar Disorder, Schizoaffective Disorder","enrollment":63},{"nctId":"NCT00645372","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":242},{"nctId":"NCT00649844","phase":"PHASE3","title":"A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-01","conditions":"Schizophrenia","enrollment":147},{"nctId":"NCT00239109","phase":"PHASE4","title":"Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-04","conditions":"Schizophrenia","enrollment":112},{"nctId":"NCT00454883","phase":"","title":"Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-04","conditions":"Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis","enrollment":379},{"nctId":"NCT00644800","phase":"PHASE4","title":"A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-07","conditions":"Schizophrenia, Mania, Delusional Disorder","enrollment":89},{"nctId":"NCT00159757","phase":"PHASE4","title":"12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT00145444","phase":"PHASE3","title":"Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-03","conditions":"Schizophrenia, Psychotic Disorders","enrollment":100},{"nctId":"NCT00634348","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-04","conditions":"Schizophrenia","enrollment":256},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT00338949","phase":"PHASE4","title":"Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2006-06","conditions":"Schizophrenia, Metabolic Syndrome X, Insulin Resistance","enrollment":77},{"nctId":"NCT04587115","phase":"EARLY_PHASE1","title":"Reducing the Abuse Liability of Prescription Opioids","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-06-16","conditions":"Addiction","enrollment":15},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":"Schizophrenia","enrollment":350},{"nctId":"NCT00458211","phase":"PHASE4","title":"Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics","status":"COMPLETED","sponsor":"Bronx Psychiatric Center","startDate":"2005-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":40},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT00248261","phase":"","title":"Ziprasidone and Sertraline in PTSD","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2005-11","conditions":"Post-traumatic Stress Disorder","enrollment":7},{"nctId":"NCT03011645","phase":"PHASE1","title":"Gene-by-Stress Interactions in Intervention Studies Significance","status":"TERMINATED","sponsor":"Duke University","startDate":"2018-05-24","conditions":"Cardiovascular Diseases","enrollment":7},{"nctId":"NCT03007303","phase":"","title":"The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients","status":"UNKNOWN","sponsor":"Dalian Seventh People's Hospital","startDate":"2016-06","conditions":"Schizophrenia, Micrognathia","enrollment":30},{"nctId":"NCT01211522","phase":"PHASE3","title":"The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2011-12-14","conditions":"Delirium, Impaired Cognition, Long Term Psychologic Disorders","enrollment":566},{"nctId":"NCT00622739","phase":"PHASE4","title":"Ziprasidone in Pediatric Bipolar Disorder","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-02","conditions":"Bipolar Disorder","enrollment":28},{"nctId":"NCT00515723","phase":"NA","title":"Glucose and Lipid Metabolism on Antipsychotic Medication","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2001-09","conditions":"Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus","enrollment":96},{"nctId":"NCT04076371","phase":"NA","title":"The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-01","conditions":"Schizophrenia","enrollment":1640},{"nctId":"NCT00288366","phase":"NA","title":"Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2006-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":49},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT00910988","phase":"NA","title":"Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-02","conditions":"Hyperglycemia, Hyperlipidemia","enrollment":46},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT03211897","phase":"","title":"Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation","status":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2017-06-15","conditions":"Agitation,Psychomotor","enrollment":737},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00667745","phase":"PHASE4","title":"Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-04","conditions":"Bipolar Disorder","enrollment":283},{"nctId":"NCT00786318","phase":"PHASE4","title":"Ziprasidone vs Standard Therapy for Agitated Patients in the ED","status":"WITHDRAWN","sponsor":"George Washington University","startDate":"2008-09","conditions":"Psychosis, Agitation, Delirium","enrollment":""},{"nctId":"NCT00403546","phase":"PHASE3","title":"High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms","status":"COMPLETED","sponsor":"Donald C. Goff, MD","startDate":"2006-01","conditions":"Schizophrenia","enrollment":131},{"nctId":"NCT00472641","phase":"PHASE4","title":"Geodon in Weight Loss Study for Bipolar Disorders","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Bipolar Disorder","enrollment":25},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT01185743","phase":"PHASE4","title":"Antipsychotics and Gene Expression in Soft Tissues","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-07","conditions":"Schizophrenia, Diabetes","enrollment":16},{"nctId":"NCT02526030","phase":"PHASE4","title":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2008-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":203},{"nctId":"NCT02305823","phase":"PHASE4","title":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2005-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":203},{"nctId":"NCT02534363","phase":"PHASE4","title":"Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2005-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":136},{"nctId":"NCT01168674","phase":"PHASE4","title":"Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2010-02","conditions":"Depression, Bipolar Disorder","enrollment":49},{"nctId":"NCT00421954","phase":"PHASE3","title":"Open-label Ziprasidone Study for Psychosis Treatment in Adolescents","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2006-05","conditions":"Schizophreniform Disorder, Schizoaffective Disorder, Psychosis","enrollment":8},{"nctId":"NCT00351000","phase":"PHASE4","title":"Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus","status":"COMPLETED","sponsor":"North Suffolk Mental Health Association","startDate":"2005-01","conditions":"Schizophrenia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"ANXIETY"},{"count":8,"reaction":"NAUSEA"},{"count":7,"reaction":"ALOPECIA"},{"count":7,"reaction":"DEPRESSION"},{"count":7,"reaction":"HEADACHE"},{"count":7,"reaction":"SUICIDAL IDEATION"},{"count":6,"reaction":"ASTHENIA"},{"count":6,"reaction":"DIARRHOEA"},{"count":6,"reaction":"DIZZINESS"},{"count":6,"reaction":"DYSPNOEA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Geodon (Ziprasidone)","genericName":"Geodon (Ziprasidone)","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Acute agitation in patients with schizophrenia, Bipolar I disorder (acute manic or mixed episodes).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}